University of East Anglia given multi-million-pound funding boost to combat...
Procarta Biosystems founder Prof Michael McArthur, from UEA's Norwich Medical School, said: "Our aim...
read moreProcarta Biosystems is a spin-out from one of Europe’s leading microbiology departments at the John Innes Centre. The company, formed in early 2008, is investigating a novel approach to counter antibiotic resistance and defeat infectious diseases using a DNA decoy technique, which aims to restore antibiotic efficacy against resistant superdrugs, such as methicillin-resistent Staphylococcus aureus (MRSA) and vancomycin-resistant Entercoccus (VRE).
Accessing the skills in the John Innes Centre, Procarta is also able to offer a contract research service creating and improving Streptomyces strains for heterologous production.
Status current
Associated Fund UK Innovation & Science Seed Fund
Sector Medical / Biotechnology
Website www.procartabio.com/
Procarta Biosystems founder Prof Michael McArthur, from UEA's Norwich Medical School, said: "Our aim...
read moreThe scientists from Procarta Biosystems, a company based at the University of East Anglia's...
read moreProcarta Biosystems has picked up €1.5m in funding to help develop a new antibiotic...
read moreAtterx Bio Therapeutics,GlycoVaxyn,Melinta Therapeutics,Soligenix,Evolva,Nymox Pharmaceutical,Syntiron,Procarta Biosystems,Phico Therapeutics ...
read moreFinally, UK-based Procarta Biosystems has received €1.5 million from the Fund. Procarta is developing...
read moreA study recently published in Nature Communications (30 June) has shown that even small...
read moreUpdate your browser to view this website correctly.Update my browser now